EC50

Overview

EC50 (half-maximal effective concentration) is the concentration of a compound that produces 50% of its maximum possible biological effect. It is the principal quantitative measure of agonist potency, providing a standardized way to compare how much of different compounds is needed to produce a given level of response.

A lower EC50 indicates greater potency — less compound is required to achieve half-maximal activation. EC50 values are expressed in molar concentrations and derived from sigmoidal dose-response curves. Together with Emax (the maximum achievable effect), EC50 fully characterizes the dose-response relationship of an agonist.

Detailed Explanation

Dose-Response Curves

EC50 is determined by exposing a biological system to increasing concentrations of an agonist and measuring the response at each concentration. When response is plotted against log concentration, the resulting curve is typically sigmoidal (S-shaped), characterized by:

• Baseline — The response level in the absence of agonist
• EC50 — The midpoint concentration producing 50% of maximal effect
• Emax — The plateau representing maximum achievable response
• Hill coefficient (n) — The slope of the curve at the EC50, reflecting cooperativity

EC50 vs. Kd

EC50 and the dissociation constant (Kd) measure related but distinct properties:

• Kd measures affinity — the concentration at which 50% of receptors are occupied
• EC50 measures functional potency — the concentration producing 50% of maximal effect

These values are not necessarily equal. If a receptor system has amplification (spare receptors), a compound may achieve 50% of maximal effect at a concentration well below its Kd, because not all receptors need to be occupied to produce a full response. Conversely, if the signaling pathway requires high receptor occupancy, EC50 may exceed Kd.

Absolute vs. Relative EC50

Absolute EC50 — The concentration producing 50% of the compound's own maximum response. This is the most commonly reported form.

Relative EC50 — The concentration producing 50% of the response achievable by a reference full agonist. For partial agonists, the relative EC50 and absolute EC50 differ because the partial agonist's maximum response is less than that of the full agonist.

Shift Experiments

Changes in EC50 under different experimental conditions provide valuable pharmacological information. A rightward shift (increased EC50) in the presence of an antagonist indicates competitive antagonism. A leftward shift (decreased EC50) in the presence of a positive allosteric modulator indicates enhanced receptor sensitivity.

Relevance to Peptide Research

EC50 is central to characterizing and comparing peptide agonists:

Growth Hormone Secretagogues — The EC50 values of different GH-releasing peptides (Ipamorelin, GHRP-6, GHRP-2) at the growth hormone secretagogue receptor define their relative potencies. A lower EC50 indicates that less peptide is needed to achieve half-maximal GH release, informing dosing considerations.

GLP-1 Receptor Agonists — Peptide analogs of GLP-1 are compared by their EC50 values at the GLP-1 receptor. Semaglutide, for example, has a substantially lower EC50 than native GLP-1, reflecting enhanced potency achieved through structural modifications that improve receptor interaction.

Peptide Analog Optimization — During the development of synthetic peptide analogs, EC50 measurement at each stage of structural modification guides optimization. Substitutions that decrease EC50 (increase potency) are retained, while those that increase EC50 are reconsidered.

Multi-Receptor Profiling — Measuring EC50 across multiple receptor subtypes reveals selectivity profiles. A peptide with an EC50 of 1 nM at its target receptor and 500 nM at a related receptor subtype has 500-fold functional selectivity.

Examples

Native GLP-1(7-36) has an EC50 at the GLP-1 receptor in the low nanomolar range but an extremely short half-life of approximately two minutes. Semaglutide, through fatty acid conjugation and strategic amino acid substitutions, maintains a comparable or lower EC50 while extending the half-life to approximately one week — illustrating how peptide engineering can preserve potency while improving pharmacokinetic properties.

In melanocortin receptor pharmacology, alpha-MSH and its synthetic analogs are characterized by their EC50 values at MC1R through MC5R subtypes, with different analogs showing distinct selectivity patterns across the receptor family.

Related Terms

EC50 is the activating counterpart to IC50, which measures inhibitory potency. Both are measures of potency, which is distinct from efficacy (the maximum achievable response). EC50 is related to affinity but influenced by receptor reserve and signal amplification. EC50 values characterize receptor agonist dose-response relationships and inform therapeutic index calculations.